The large number of patient participants at the American Society of Nephrology’s Kidney Week 2019 meeting reflects the understanding that patients should be elevated in the conversations around kidney care, said Paul Conway, chair of global affairs and public policy and immediate past president, American Association of Kidney Patients.
The large number of patient participants at the American Society of Nephrology (ASN)’s Kidney Week 2019 meeting reflects the understanding that patients should be elevated in the conversations around kidney care, said Paul Conway, chair of global affairs and public policy and immediate past president, American Association of Kidney Patients.
What are the best practices for engaging patients in their kidney care?
Well, first of all is respect, and the second one I think is listening to patients. So here we are at the largest kidney meeting in the world, an overwhelming number of nephrologists and researchers and that type of thing, and I think what’s nice this year about ASN is it’s the largest number of patient participants that are involved. It was the dedication of ASN to focus on that, and that’s a sign of something that answers your question, which is if you don’t respect a patient and take the time to listen and elevate the patient in the conversation, then you’re never really going to get all the other patients that they talk to to the point where they’re willing to open up and be engaged. So that’s an important thing, showing that you have an interest in listening.
But I think the most important strategic element that anybody that interacts with a patient has to keep in mind is this: The ideal standard of care is a treatment that matches the aspirations of the patient. And people miss this a lot, but if you want to have a job and you want to keep working, you want to have a family or have a car, put away money for retirement, visit your grandkids, you need to talk to that patient about the best care and best modality of care that they need to stay mobile and stay engaged in life.
I think that’s probably, if you start the conversation there, then everything else follows. But when a professional seems as if they don’t have enough time or they don’t care or they stereotype an individual as, let’s say, they’re overweight or they may be diabetic and “that person doesn’t take care of themselves, therefore I don’t need to invest more time in trying to figure out what they really want to do or talk to them about nutrition,” that’s when I think the doors and the barriers go up.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More